exceet Group SE

  • WKN: A0YF5P
  • ISIN: LU0472835155
  • Land: Luxemburg

Nachricht vom 10.10.2019 | 18:06

exceet Group SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

exceet Group SE

10.10.2019 / 18:06
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


To:

The board of directors of exceet Group SE ('exceet')

C/o Wolf-Günther Freese, CEO of exceet

___ October 2019

Re: Notification of AIFM appointment

Ladies and Gentlemen,

White Elephant S.à r.l. is a société à responabilité limitée incorporated under the laws of Luxembourg, having its registered office c/o navAXX S.A., 17, rue de Flaxweiler, L-6776 Grevenmacher, Grand Duchy of Luxembourg and being registered with the Luxembourg trade and companies register (Registre de Commerce et des Sociétés, Luxembourg) (the 'RCS') under number B 217.931 ('White Elephant').

White Elephant is a wholly-owned subsidiary of White Elephant Holdco S.à r.l., which is in turn controlled by Active Ownership Fund SICAV-SIF, SCS, a société en commandite simple incorporated under the laws of Luxembourg, having its registered office c/o navAXX S.A., 17, rue de Flaxweiler, L-6776 Grevenmacher, Grand Duchy of Luxembourg and being registered with the RCS under number B 200.454 ('AOF'). AOF is controlled by its general partner, Active Ownership Capital S.à r.l., a société à responabilité limitée incorporated under the laws of Luxembourg, having its registered office c/o navAXX S.A., 17, rue de Flaxweiler, L-6776 Grevenmacher, Grand Duchy of Luxembourg and being registered with the RCS under number B 200.367 (the 'General Partner').

Active Ownership Corporation S.à r.l., a société à responabilité limitée incorporated under the laws of Luxembourg, having its registered office c/o navAXX S.A., 17, rue de Flaxweiler, L-6776 Grevenmacher, Grand Duchy of Luxembourg and being registered with the RCS under number B 237.258 ('AOC'), has on 1 October 2019 been appointed as alternative investment fund manager (within the meaning of the law of 12 July 2013 on alternative investment fund managers, as amended) of AOF.

AOC is, pursuant to the relevant appointment agreement (AIFM-Bestellungsvertrag), entitled to exercise in its sole discretion all rights arising from participations and other assets of AOF including, but not limited, voting rights attaching to shares and in particular the 11,813,721 shares in exceet held by White Elephant.

For the avoidance of doubt, AOC is ultimately controlled by the same natural persons ultimately controlling the General Partner. There has consequently been a change to the chain of entities controlling White Elephant, but no change of control with respect to White Elephant.

[This notice is issued pursuant to article 7.4 of the articles of association of exceet.]

Sincerely,

White Elephant S.à r.l.

 

____________________
By:
Title: Manager
____________________
By:
Title: Manager
 

 

 



10.10.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Anleihe im Fokus

„Semper idem Underberg AG: Emission neuer Unternehmensanleihe 2019/2025“

- Emissionsvolumen: bis zu 60 Mio. Euro
- Anleihenumtausch: 23.010. bis 06.11.2019
- Neuzeichnung: 07.11. bis 12.11.2019
- ISIN: DE000A2YPAJ3 / WKN: A2YPAJ
- Stückelung / Mindestanlage: 1.000 Euro
- Zinssatz (Kupon):
Liegt in einer Spanne von 4,00 % bis 4,25 % p.a.
- Laufzeit: 6 Jahre
- Zinszahlung: jährlich, jeweils am 18. November (nachträglich), erstmals am 18. November 2020
- Rückzahlungskurs: 100%
- Fälligkeit: 18. November 2025
- Listing: Listing im Freiverkehr (Open Market) der Frankfurter Wertpapierbörse vorgesehen

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Wirecard AG beauftragt unabhängige Prüfung

21. Oktober 2019, 07:40

Aktuelle Research-Studie

CO.DON AG

Original-Research: CO.DON AG (von Sphene Capital GmbH): Buy

21. Oktober 2019